Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome

Andrew R. Chapman(University of Edinburgh), Kuan Ken Lee(University of Edinburgh), David McAllister(University of Glasgow), Louise Cullen(Queensland University of Technology), Jaimi Greenslade(Queensland University of Technology), William Parsonage(Queensland University of Technology), Andrew Worster(McMaster University), Peter A. Kavsak(McMaster University), Stefan Blankenberg(Universität Hamburg), Franz–Josef Neumann(Universität Hamburg), Nils A. Sörensen(Universität Hamburg), Dirk Westermann(Universität Hamburg), Madelon M. Buijs(DDL Diagnostic Laboratory), Gerard Verdel(Spaarne Gasthuis), John W. Pickering(Christchurch Hospital), Martin Than(Christchurch Hospital), Raphael Twerenbold(University Hospital of Basel), Patrick Badertscher(University Hospital of Basel), Zaid Sabti(University Hospital of Basel), Christian Mueller(University Hospital of Basel), Atul Anand(University of Edinburgh), Philip D Adamson(University of Edinburgh), Fiona E. Strachan(University of Edinburgh), Amy V. Ferry(University of Edinburgh), Dennis Sandeman(University of Edinburgh), Alasdair Gray(Edinburgh Royal Infirmary), Richard Body(University of Manchester), Brian Keevil(Manchester University NHS Foundation Trust), Edward Carlton(Southmead Hospital), Kim Greaves(University of the Sunshine Coast), Frederick K. Korley(University of Michigan), Thomas S. Metkus, Yader Sandoval(Abbott Northwestern Hospital), Fred S. Apple(University of Minnesota), David E. Newby(University of Edinburgh), Anoop Shah(University of Edinburgh), Nicholas L. Mills(University of Edinburgh)
JAMA
November 11, 2017
Cited by 249Open Access
Full Text

Abstract

Importance: High-sensitivity cardiac troponin I testing is widely used to evaluate patients with suspected acute coronary syndrome. A cardiac troponin concentration of less than 5 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain. Objective: To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation as a risk stratification tool in patients with suspected acute coronary syndrome. Data Sources: Systematic search of MEDLINE, EMBASE, Cochrane, and Web of Science databases from January 1, 2006, to March 18, 2017. Study Selection: Prospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjudicated according to the universal definition of myocardial infarction. Data Extraction and Synthesis: The systematic review identified 19 cohorts. Individual patient-level data were obtained from the corresponding authors of 17 cohorts, with aggregate data from 2 cohorts. Meta-estimates for primary and secondary outcomes were derived using a binomial-normal random-effects model. Main Outcomes and Measures: The primary outcome was myocardial infarction or cardiac death at 30 days. Performance was evaluated in subgroups and across a range of troponin concentrations (2-16 ng/L) using individual patient data. Results: Of 11 845 articles identified, 104 underwent full-text review, and 19 cohorts from 9 countries were included. Among 22 457 patients included in the meta-analysis (mean age, 62 [SD, 15.5] years; n = 9329 women [41.5%]), the primary outcome occurred in 2786 (12.4%). Cardiac troponin I concentrations were less than 5 ng/L at presentation in 11 012 patients (49%), in whom there were 60 missed index or 30-day events (59 index myocardial infarctions, 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days). This resulted in a negative predictive value of 99.5% (95% CI, 99.3%-99.6%) for the primary outcome. There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a negative predictive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death. Conclusions and Relevance: Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death within 30 days. Further research is needed to understand the clinical utility and cost-effectiveness of this approach to risk stratification.


Related Papers

No related papers found

Powered by citation graph analysis